Results 181 to 190 of about 22,517 (214)
Some of the next articles are maybe not open access.
Octreotide and Gastrointestinal Fistulae
Digestion, 1990The place of somatostatin and its analogues in the management of gastrointestinal fistulae is reviewed, drawing attention to the difficulty of assessing treatments that influence spontaneous closure. Sixteen patients with gastric, small bowel, and pancreatic fistulae were randomized to receive octreotide injections (100 micrograms t.i.d.) or placebo ...
S. Finnegan, M.H. Irving, N.A. Scott
openaire +3 more sources
Experiences with octreotide in acromegaly
Irish Journal of Medical Science, 1993We report experiences in 3 patients with acromegaly while using the somatostatin analogue octreotide. In case 1, a 44 year old male developed pneumococcal meningitis 3 months after having transphenoidal surgery for a pituitary tumour. This occurred with the re-emergence of communication between the surgical tract and the C.S.F.
J. A. O’Hare, F. Abuaisha, T. Cotter
openaire +3 more sources
Annals of Pharmacotherapy, 1997
In a limited number of case reports in infants, octreotide raised the blood glucose concentrations and decreased glucose requirements sufficiently to avoid pancreatectomy. This response occurs in the presence of frequent feedings and diazoxide therapy, and lasts from 1 month to greater than 5 years.
openaire +3 more sources
In a limited number of case reports in infants, octreotide raised the blood glucose concentrations and decreased glucose requirements sufficiently to avoid pancreatectomy. This response occurs in the presence of frequent feedings and diazoxide therapy, and lasts from 1 month to greater than 5 years.
openaire +3 more sources
Presurgical octreotide treatment in acromegaly
Metabolism, 1992The effects of octreotide pretreatment before surgery were assessed in 48 acromegalic patients who underwent trans-sphenoidal surgery to remove pituitary adenoma, and compared with 107 patients who did not receive octreotide before surgery. Pretreated patients received octreotide 100 micrograms, thrice daily for 3 to 6 weeks (group 1), or 100 to 500 ...
A, Stevenaert +3 more
openaire +5 more sources
Octreotide-Associated Neutropenia
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2017Drug-induced neutropenia and agranulocytosis are rare adverse events but can be fatal. Neutropenia can be induced by a myriad of drugs from almost every pharmacologic class. Octreotide is a somatostatin analog that has been used to treat variceal bleeding, acromegaly, and severe diarrhea associated with metastatic tumors, and to reduce symptoms in the ...
Stacy S. Tse, Troy Kish
openaire +2 more sources
Octreotide Treatment of Acromegaly
Hormone Research, 1990The experience of St Bartholomew's Hospital in the treatment of acromegaly with octreotide is presented. When administered intravenously and subcutaneously, octreotide had a longer circulating half-life than natural somatostatin. Subcutaneous octreotide in a range of doses (50-400 micrograms) caused a very similar degree of growth hormone (GH ...
openaire +3 more sources
Octreotide and Potassium Homeostasis
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1997Somatostatin infusion causes hyperkalemia in healthy subjects and in some animal models. The purpose of this investigation was to determine what effect octreotide has on potassium homeostasis during serious illness and if there is a dose‐response relationship.
Rex O. Brown +5 more
openaire +3 more sources
Clinical Endocrinology, 1997
OBJECTIVE Octreotide scintigraphy has been reported to visualize chromaffine tumours. This study in patients with malignant phaeochromocytoma was designed to assess octreotide in comparison with standard m‐iodobenzylguanidine (MIBG) scintigraphy and to study functional activity of somatostatin receptors.
Kopf, D. +7 more
openaire +3 more sources
OBJECTIVE Octreotide scintigraphy has been reported to visualize chromaffine tumours. This study in patients with malignant phaeochromocytoma was designed to assess octreotide in comparison with standard m‐iodobenzylguanidine (MIBG) scintigraphy and to study functional activity of somatostatin receptors.
Kopf, D. +7 more
openaire +3 more sources
Octreotide for acromegaly treatment: a reappraisal
Expert Opinion on Pharmacotherapy, 2013Acromegaly is a rare disorder characterized by excess secretion of growth hormone (GH) generally caused by a pituitary macroadenoma and associated with reduced life expectancy if the disease is untreated. This article covers the recent available evidences published on octreotide , the first somatostatin analog introduced into clinical practice for the ...
GIUSTINA, Andrea +3 more
openaire +4 more sources
Octreotide in the Management of Postoperative Chylothorax
Pediatric Cardiology, 2004Chylothorax (KT) may be a complication of thoracic surgery. Its management is not well established and may comprise dietary interventions and surgery. The effectiveness of somatostatin and its analogues has been reported, although their mechanism(s) of action is unclear.
L. Rosti +10 more
openaire +3 more sources